Lopez Andres, Parsons Ainslie B, Nislow Corey, Giaever Guri, Boone Charles
Banting and Best Department of Medical Research and Department of Medical Genetics and Microbiology, Terrence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, 160 College Street, Toronto, Canada.
Prog Drug Res. 2008;66:237, 239-71. doi: 10.1007/978-3-7643-8595-8_5.
Determining the mode of action of bioactive compounds, including natural products, is a central problem in chemical biology. Because many genes are conserved from the yeast Saccharomyces cerevisiae to humans and a number of powerful genomics tools and methodologies have been developed for this model system, yeast is making a major contribution to the field of chemical genetics. The set of barcoded yeast deletion mutants, including the set of approximately 5000 viable haploid and homozygous diploid deletion mutants and the complete set of approximately 6000 heterozygous deletion mutants, containing the set of approximately 1000 essential genes, are proving highly informative for identifying chemical-genetic interactions and deciphering compound mode of action. Gene deletions that render cells hypersensitive to a specific drug identify pathways that buffer the cell against the toxic effects of the drug and thereby provide clues about both gene and compound function. Moreover, compounds that show similar chemical-genetic profiles often perturb similar target pathways. Gene dosage can be exploited to discover connections between compounds and their targets. For example, haploinsufficiency profiling of an antifungal compound, in which the set of approximately 6000 heterozygous diploid deletion mutants are scored for hypersensitivity to a compound, may identify the target directly. Creating deletion mutant collections in other fungal species, including the major human fungal pathogen Candida albicans, will expand our chemical genomics tool set, allowing us to screen for antifungal lead drugs directly. The yeast deletion mutant collection is also being exploited to map large-scale genetic interaction data obtained from genome-wide synthetic lethal screens and the integration of this data with chemical genetic data should provide a powerful system for linking compounds to their target pathway. Extensive application of chemical genetics in yeast has the potential to develop a small molecule inhibitor for the majority of all approximately 6000 yeast genes.
确定生物活性化合物(包括天然产物)的作用模式是化学生物学中的核心问题。由于从酿酒酵母到人类的许多基因是保守的,并且已经为这个模式系统开发了许多强大的基因组学工具和方法,酵母正在为化学遗传学领域做出重大贡献。一组带有条形码的酵母缺失突变体,包括大约5000个存活的单倍体和纯合二倍体缺失突变体以及大约6000个杂合缺失突变体的完整集合,其中包含大约1000个必需基因,已被证明对于识别化学-遗传相互作用和解读化合物作用模式具有高度信息价值。使细胞对特定药物超敏感的基因缺失可识别缓冲细胞免受药物毒性影响的途径,从而提供有关基因和化合物功能的线索。此外,显示相似化学-遗传图谱的化合物通常会干扰相似的靶标途径。基因剂量可用于发现化合物与其靶标之间的联系。例如,对抗真菌化合物进行单倍体不足分析,即对大约6000个杂合二倍体缺失突变体集合进行对化合物超敏感性评分,可能直接识别靶标。在其他真菌物种(包括主要的人类真菌病原体白色念珠菌)中创建缺失突变体集合,将扩展我们的化学基因组学工具集,使我们能够直接筛选抗真菌先导药物。酵母缺失突变体集合也正在被用于绘制从全基因组合成致死筛选获得的大规模遗传相互作用数据,并且将这些数据与化学遗传数据整合应该提供一个强大的系统,用于将化合物与其靶标途径联系起来。在酵母中广泛应用化学遗传学有潜力为所有大约6000个酵母基因中的大多数开发小分子抑制剂。